169 related articles for article (PubMed ID: 19780253)
1. Counterpoint: routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological malignancies.
Kleinberg M
J Natl Compr Canc Netw; 2004 Sep; 2(5):445-51. PubMed ID: 19780253
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
Gafter-Gvili A; Fraser A; Paul M; Leibovici L
Ann Intern Med; 2005 Jun; 142(12 Pt 1):979-95. PubMed ID: 15968013
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies.
Nenova IS; Ananostev NH; Goranov SE; Mateva NG; Haidushka IA
Folia Med (Plovdiv); 2001; 43(4):40-5. PubMed ID: 12087953
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
6. Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series.
Wojenski DJ; Barreto JN; Wolf RC; Tosh PK
Clin Ther; 2014 Jun; 36(6):976-81. PubMed ID: 24832560
[TBL] [Abstract][Full Text] [Related]
7. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S
Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298
[TBL] [Abstract][Full Text] [Related]
8. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
9. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely.
Bow EJ
J Natl Compr Canc Netw; 2004 Sep; 2(5):433-44. PubMed ID: 19780252
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
Gafter-Gvili A; Fraser A; Paul M; van de Wetering M; Kremer L; Leibovici L
Cochrane Database Syst Rev; 2005 Oct; (4):CD004386. PubMed ID: 16235360
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
[TBL] [Abstract][Full Text] [Related]
13. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Nguyen AD; Heil EL; Patel NK; Duffy A; Gilmore S
J Oncol Pharm Pract; 2016 Apr; 22(2):303-7. PubMed ID: 25567517
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
15. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.
Slavin MA; Lingaratnam S; Mileshkin L; Booth DL; Cain MJ; Ritchie DS; Wei A; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):102-9. PubMed ID: 21272174
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider.
Lo N; Cullen M
Hematol Oncol; 2006 Sep; 24(3):120-5. PubMed ID: 16783844
[TBL] [Abstract][Full Text] [Related]
17. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
[TBL] [Abstract][Full Text] [Related]
18. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.
Mikulska M; Averbuch D; Tissot F; Cordonnier C; Akova M; Calandra T; Ceppi M; Bruzzi P; Viscoli C;
J Infect; 2018 Jan; 76(1):20-37. PubMed ID: 29079323
[TBL] [Abstract][Full Text] [Related]
20. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
